{
    "organizations": [],
    "uuid": "63512490ab6d7023a5729ba33338e6be890296b3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-syros-pharmaceuticals-reports-q1-l/brief-syros-pharmaceuticals-reports-q1-loss-per-share-of-0-48-idUSASC0A1DZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Syros Pharmaceuticals Reports Q1 Loss Per Share Of $0.48",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10, 2018 / 11:39 AM / Updated 13 minutes ago BRIEF-Syros Pharmaceuticals Reports Q1 Loss Per Share Of $0.48 Reuters Staff\nMay 10 (Reuters) - Syros Pharmaceuticals Inc:\n* SYROS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS KEY ACCOMPLISHMENTS AND UPCOMING MILESTONES * Q1 REVENUE VIEW $4 MILLION — THOMSON REUTERS I/B/E/S\n* Q1 EARNINGS PER SHARE VIEW $-0.39 — THOMSON REUTERS I/B/E/S\n* SYROS PHARMACEUTICALS - PLAN TO OPEN SINGLE-AGENT, COMBINATION EXPANSION COHORTS IN PHASE 1 TRIAL OF SY-1365 IN MID-2018\n* SYROS - EXPECT TO REPORT INITIAL DATA FROM COMBINATION ARMS OF PHASE 2 TRIAL OF SY-1425, DOSE ESCALATION PORTION OF PHASE 1 TRIAL OF SY-1365 IN Q4 2018\n* SYROS PHARMACEUTICALS - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2018 WERE $121.7 MILLION, VERSUS $72.0 MILLION ON DEC 31, 2017\n* SYROS - BELIEVES EXISTING CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES TO BE SUFFICIENT TO ENABLE CO TO FUND PLANNED OPERATING EXPENSES INTO 2020 Source text for Eikon: Further company coverage:",
    "published": "2018-05-10T14:38:00.000+03:00",
    "crawled": "2018-05-10T14:55:15.082+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "updated",
        "minute",
        "ago",
        "pharmaceutical",
        "report",
        "q1",
        "loss",
        "per",
        "share",
        "reuters",
        "staff",
        "may",
        "reuters",
        "syros",
        "pharmaceutical",
        "inc",
        "syros",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "highlight",
        "key",
        "accomplishment",
        "upcoming",
        "milestone",
        "q1",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "syros",
        "pharmaceutical",
        "plan",
        "open",
        "combination",
        "expansion",
        "cohort",
        "phase",
        "trial",
        "syros",
        "expect",
        "report",
        "initial",
        "data",
        "combination",
        "arm",
        "phase",
        "trial",
        "dose",
        "escalation",
        "portion",
        "phase",
        "trial",
        "q4",
        "syros",
        "pharmaceutical",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "march",
        "million",
        "versus",
        "million",
        "dec",
        "syros",
        "belief",
        "existing",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "sufficient",
        "enable",
        "co",
        "fund",
        "planned",
        "operating",
        "expense",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}